Tesla Motors, Inc. TSLA – Options
Yesterday, those of our readers following our recent coverage of TSLA were once again presented with opportunities coming out of the 05/22 $230-240 Calls that we’ve been monitoring since Friday. TSLA registered a higher high and a higher low for the fifth consecutive session, topping out at 248.30. As a result, the total possible gains on our initial calls were pushed even further into the green, so we wanted to provide an update on those figures:
$230 Calls – Friday’s Low: 6.85 – Yesterday’s High: 17.95 – Max Gain: 162%
$232.50 Calls – Friday’s Low: 5.32 – Yesterday’s High: 16.90 – Max Gain: 217%
$235 Calls – Friday’s Low: 5.96 – Yesterday’s High: 13.95 – Max Gain: 134%
$237.50 Calls – Friday’s Low: 3.16 – Yesterday’s High: 12.00 – Max Gain: 280%
$240 Calls – Friday’s Low: 3.84 – Yesterday’s High: 10.50 – Max Gain: 173%
These moves are a perfect example of what draws us to options trading; with just a 6% increase in TSLA stock, we’ve witnessed huge gains across the board in the options chain. These contracts don’t expire until next Friday, so we’ll keep our fingers on TSLA’s pulse until that time.
AcelRx Pharmaceuticals, Inc. ACRX
Popping up on our scanner this morning is a play that has both an interesting chart as well as a blockbuster PR out today that is leading to a gap-up in premarket trading (3.30-3.80’s).
We’re catching the stock as it comes up off of a relative bottom, and as we point out on the snapshot below, there are several attractive features of the current ACRX chart.
Couple that with this morning’s revelation of a contract the company has struck with the US Dept. of Defense, and ACRX becomes instantly worthy of our attention as the week draws to a close.
- AcelRx Awarded Contract from Department of Defense to Advance ARX-04 (Thu 7:00AM EDT)
Discovery Laboratories, Inc. DSCO
Speaking of pharma stocks with fresh news, DCSO is also cropping up on our scanner this morning. Like the aforementioned play, this morning/s PR is resulting in a gap-up, and we’ll want to have our eyes peeled for potential advantageous activity on the chart once the session commences.
According to the release, Phase II testing of its AEROSURF® product has yielded “encouraging safety and physiological data suggest that aerosolized KL4 surfactant can be delivered to the lung of premature infants with respiratory distress syndrome”
PTBI, CYRN, BAA, CDTI, WOGI